Skip to main content
SpringerLink
Log in

Prescribing Antiepileptic Drugs

Should Patients Be Switched on the Basis of Cost?

  • Current Opinion
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

To assess the costs of switching from one antiepileptic drug (AED) to another, all associated direct and indirect costs, not only drug acquisition costs, must be considered. The perspective of the healthcare system evaluated in cost-effectiveness analysis is of crucial importance. Multiple clinical factors can influence clinical decisions regarding switching AEDs. The economic cost of poorly controlled epilepsy is enormous and the most cost-effective intervention is an AED that provides total seizure control. Cost-minimisation studies have evaluated costs associated with various medications. If only efficacy and adverse events were considered, then the ‘older’ AEDs were generally more cost effective than the ‘newer’ AEDs. Most studies only examine very specific clinical situations and are not suitable for establishing general clinical recommendations. The pharmacoeconomics of AED choice is highly country specific. While switching to generic formulations is, in general, cost effective, some changes may be detrimental and more costly than remaining on the trade name preparation. For example, as a result of differences in bioavailability and possible loss of seizure control, changing patients to generic phenytoin and carbamazepine can be problematic. Fosphenytoin may only be cost effective in certain clinical situations compared with intravenous phenytoin. Seizure control should not be sacrificed on the basis of costs alone, as the major endpoint in treating epilepsy with AEDs is seizure control without adverse effects. Switching AEDs in clinical practice still depends on the individual clinical situation and choosing AED therapy solely on the basis of initial acquisition costs is unlikely to be cost effective in the long-term care of patients with epilepsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Heaney DC, Sander JWAS. Ensuring appropriate care in epilepsy: an overview of epidemiological and cost of illness considerations. Dis Manag Health Outcomes 1998; 4: 303–13

    Article  Google Scholar 

  2. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41(3): 342–51

    Article  PubMed  CAS  Google Scholar 

  3. Cockerell OC, Hart YM, Sander JW, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994; 18(3): 249–60

    Article  PubMed  CAS  Google Scholar 

  4. Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17(2): 197–208

    Article  PubMed  CAS  Google Scholar 

  5. Boon P, D’Have M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002; 43(1): 96–102

    Article  PubMed  CAS  Google Scholar 

  6. British National Formulary [online]. Available from URL: http://www.bnf.org. [Accessed 2003 Sep]

  7. Heaney DC, Shorvon SD, Sander JW, et al. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 2 European countries. Epilepsia 2000; 41Suppl. 5: S37–44

    PubMed  Google Scholar 

  8. Daranzi Y, Mikati M. Treatment-refractory epilepsy: an overview of treatment options and costs. Dis Manag Health Outcomes 1997; 2: 111–23

    Article  Google Scholar 

  9. Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35(6): 1230–43

    Article  PubMed  CAS  Google Scholar 

  10. Maltoni S, Messori A. Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy. Clin Drug Invest 2003; 23(4): 225–32

    Article  CAS  Google Scholar 

  11. Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure 1999; 8(1): 8–13

    Article  PubMed  CAS  Google Scholar 

  12. van Hout B, Gagnon D, McNulty P, et al. The cost effectiveness of two antiepileptic therapies in the absence of direct comparative data. Pharmacoeconomics 2003; 21(5): 315–26

    Article  PubMed  Google Scholar 

  13. Levy P. Economic evaluation of antiepileptic drug therapy: a ethodologic review. Epilepsia 2002; 43(5): 550–8

    Article  PubMed  Google Scholar 

  14. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276(15): 1253–8

    Article  PubMed  CAS  Google Scholar 

  15. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996; 37Suppl. 2: S1–3

    Article  PubMed  Google Scholar 

  16. Nashef L, Fish DR, Garner S, et al. Sudden death in epilepsy: a study of incidence in a young cohort with epilepsy and learning difficulty. Epilepsia 1995; 36(12): 1187–94

    Article  PubMed  CAS  Google Scholar 

  17. Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46(1): 45–50

    Article  PubMed  CAS  Google Scholar 

  18. Wirrell EC, Camfield PR, Camfield CS, et al. Accidental injury is a serious risk in children with typical absence epilepsy. Arch Neurol 1996; 53(9): 929–32

    Article  PubMed  CAS  Google Scholar 

  19. Jones MW. Consequences of epilepsy: why do we treat seizures? Can J Neurol Sci 1998; 25(4): S24–6

    PubMed  CAS  Google Scholar 

  20. Appelton R, Group MRPEI. Seizure-related injuries in children with newly diagnosed epilepsy. Epilepsia 2002; 43: 764–7

    Article  Google Scholar 

  21. Baker GA, Nashef L, van Hout BA. Current issues in the management of epilepsy: the impact of frequent seizures on cost of illness, quality of life, and mortality. Epilepsia 1997; 38Suppl. 1: S1–8

    Article  PubMed  Google Scholar 

  22. Baker G, Jacoby A, Buck D, et al. Quality of life of people with epilepsy: a European study. Epilepsia 1997; 38: 353–62

    Article  PubMed  CAS  Google Scholar 

  23. van Hout B, Gagnon D, Souetre E, et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kindgom. Epilepsia 1997; 38(11): 1221–6

    Article  PubMed  Google Scholar 

  24. Bourgeois BF, Prensky AL, Palkes HS, et al. Intelligence in epilepsy: aprospective study in children. Ann Neurol 1983; 14(4): 438–44

    Article  PubMed  CAS  Google Scholar 

  25. Helmstaedter C, Kurthen M, Lux S, et al. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol 2003; 54(4): 425–32

    Article  PubMed  Google Scholar 

  26. Hermann BP, Seidenberg M, Bell B. The neurodevelopmental impact of childhood onset temporal lobe epilepsy on brain structure and function and the risk of progressive cognitive effects. Prog Brain Res 2002; 135: 429–38

    Article  PubMed  Google Scholar 

  27. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985; 313(3): 145–51

    Article  PubMed  CAS  Google Scholar 

  28. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327(11): 765–71

    CAS  Google Scholar 

  29. Navarro R, Ashraf T. Cost analysis of carbamazepine, phenytoin, and valproate for the use in complex partial seizures. Med Interface 1993; 6: 113–8

    Google Scholar 

  30. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. ancet 1995; 345(8948): 476–9

    CAS  Google Scholar 

  31. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998; 7: 119–25

    PubMed  CAS  Google Scholar 

  32. Heaney DC, Shorvon SD, Sander JW. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39Suppl. 3: S19–25

    Article  PubMed  CAS  Google Scholar 

  33. Lathers CM, Schraeder PL, Claycamp HG. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 2003; 43(5): 491–503

    PubMed  CAS  Google Scholar 

  34. Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80(2): 165–74

    PubMed  CAS  Google Scholar 

  35. Camfield CS, Chaplin S, Doyle AB, et al. Side effects of phenobarbital in toddlers; behavioral and cognitive aspects. J Pediatr 1979; 95(3): 361–5

    Article  PubMed  CAS  Google Scholar 

  36. de Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347(9003): 709–13

    Article  PubMed  Google Scholar 

  37. Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998; 53(6): 421–7

    Article  PubMed  CAS  Google Scholar 

  38. O’Neill B, Trimble M, Bloom D. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995; 4: 37–44

    Article  PubMed  Google Scholar 

  39. Hughes D, Cockerell OC. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy. Seizure 1996; 5(2): 89–95

    PubMed  CAS  Google Scholar 

  40. Miller P, Millac P. Audit of the management of patients with refractory epilepsy. Seizure 1994; 3(4): 295–9

    Article  Google Scholar 

  41. McLachlan RS, Maher J. Management of antiepileptic drugs following epilepsy surgery: a review. Can J Neurol Sci 2000; 27Suppl. 1: S106–10

    PubMed  Google Scholar 

  42. Wilner AN. Physicians underestimate the frequency of generic carbamazepine substitution: results of a survey and review of the problem. Epilepsy Behav 2002; 3(6): 522–5

    Article  PubMed  Google Scholar 

  43. Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970; 4(730): 271–3

    Article  PubMed  CAS  Google Scholar 

  44. Besag FM. Is generic prescribing acceptable in epilepsy? Drug Saf 2000; 23(3): 173–82

    Article  PubMed  CAS  Google Scholar 

  45. Crawford P, Hall WW, Chappell B, et al. Generic prescribing for epilepsy: is it safe? Seizure 1996; 5(1): 1–5

    Article  PubMed  CAS  Google Scholar 

  46. Rosenbaum DH, Rowan AJ, Tuchman L, et al. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994; 35(3): 656–60

    Article  PubMed  CAS  Google Scholar 

  47. Chen SS, Allen J, Oxley J, et al. Comparative bioavailability of phenytoin from generic formulations in the United Kingdom. Epilepsia 1982; 23(2): 149–52

    Article  PubMed  CAS  Google Scholar 

  48. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55(8): 688–91

    Article  PubMed  CAS  Google Scholar 

  49. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990; 40 (11): 1641–3

    Google Scholar 

  50. Welty TE, Pickering PR, Hale BC, et al. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992; 26(6): 775–7

    PubMed  CAS  Google Scholar 

  51. Revankar SN, Desai ND, Bhatt AD, et al. Comparison of absorption rate and bioavailability of two brands of carbamazepine. J Assoc Physicians India 1999; 47(7): 699–702

    PubMed  CAS  Google Scholar 

  52. Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 1997; 31(5): 548–52

    PubMed  CAS  Google Scholar 

  53. Oles KS, Penry JK, Smith LD, et al. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992; 42(6): 1147–53

    Article  PubMed  CAS  Google Scholar 

  54. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology 1987; 37(12): 1885

    Article  PubMed  CAS  Google Scholar 

  55. Vadney VJ, Kraushaar KW. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment Retard 1997; 35(6): 468–72

    Article  PubMed  CAS  Google Scholar 

  56. Sherwood Brown E, Shellhorn E, Suppes T. Gastrointestinal side-effects after switch to generic valproic acid. Pharmacopsychiatry 1998; 31(3): 114

    Article  PubMed  CAS  Google Scholar 

  57. DeToledo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf 2000; 22(6): 459–66

    Article  PubMed  CAS  Google Scholar 

  58. Marchetti A, Magar R, Fischer J, et al. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous henytoin (Dilantin) in hospital emergency departments. Clin Ther 1996; 18(5): 953–66

    Article  PubMed  CAS  Google Scholar 

  59. Touchette DR, Rhoney DH. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Pharmacotherapy 2000; 20(8): 908–16

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by grants from the Western Massachusetts Epilepsy Awareness Committee and NINDS (NS27983) to GLH. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Neuroscience Center at Dartmouth, Section of Neurology, Dartmouth Medical School, Hanover, New Hampshire, USA

    Barbara C. Jobst & Gregory L. Holmes

Authors
  1. Barbara C. Jobst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory L. Holmes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barbara C. Jobst.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jobst, B.C., Holmes, G.L. Prescribing Antiepileptic Drugs. CNS Drugs 18, 617–628 (2004). https://doi.org/10.2165/00023210-200418100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418100-00001

Keywords

Search

Navigation